April 12, 2013 at 10:21 AM EDT
UPDATE: Jefferies Raises PT on ACADIA Pharmaceuticals Following FDA Discussions
In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD ), and raised the price target from $13.00 to $18.00. In the report, Wei noted, “Following discussions with the FDA, ACAD announced that it intends to file for pimavanserin in Parkinson's disease
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here